1 day Ago By ABMN Staff
Legal & General Group Plc cut its stake in shares of Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT – Free Report ) by 8.0% during the 4th quarter, HoldingsChannel reports.
The institutional investor owned 24,147 shares of the biotechnology company’s stock after selling 2,108 shares during the period. Legal & General Group Plc’s holdings in Arcturus Therapeutics were worth $410,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also recently modified their holdings of ARCT.
Wells Fargo & Company MN increased its holdings in Arcturus Therapeutics by 12.6% during the 4th quarter. Wells Fargo & Company MN now owns 69,664 shares of the biotechnology company’s stock worth $1,182,000 after acquiring an additional 7,785 shares during the period.
Massachusetts Financial Services Co. MA raised its position in shares of Arcturus Therapeutics by 22.2% in the fourth quarter.
Massachusetts Financial Services Co. MA now owns 59,817 shares of the biotechnology company’s stock worth $1,015,000 after buying an additional 10,860 shares in the last quarter. Geode Capital Management LLC boosted its stake in Arcturus Therapeutics by 0.
6% during the fourth quarter. Geode Capital Management LLC now owns 554,984 shares of the biotechnology company’s stock valued at $9,421,000 after buying an additional 3,186 shares during the period. National Bank of Canada FI grew its position in Arcturus Therapeutics by 639.
6% during the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock worth $94,000 after buying an additional 4,784 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in Arcturus Therapeutics by 0.
8% in the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock worth $1,647,000 after acquiring an additional 742 shares during the last quarter. 94.
54% of the stock is owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth Several brokerages have recently commented on ARCT. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th.
BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 10th. Canaccord Genuity Group dropped their price objective on shares of Arcturus Therapeutics from $74.
00 to $68.00 and set a “buy” rating for the company in a report on Monday, March 10th. HC Wainwright reiterated a “buy” rating and issued a $60.
00 target price on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Finally, Wells Fargo & Company lowered their price target on Arcturus Therapeutics from $58.00 to $50.
00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.
com, Arcturus Therapeutics presently has an average rating of “Buy” and a consensus target price of $59.20. Arcturus Therapeutics Stock Performance Shares of NASDAQ:ARCT opened at $12.
82 on Wednesday. Arcturus Therapeutics Holdings Inc. has a 12-month low of $8.
04 and a 12-month high of $45.00. The stock’s 50-day moving average price is $12.
60 and its 200-day moving average price is $15.94. The stock has a market capitalization of $347.
68 million, a P/E ratio of -5.77 and a beta of 3.41.
Arcturus Therapeutics ( NASDAQ:ARCT – Get Free Report ) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.
33) by ($0.78). The company had revenue of $22.
77 million during the quarter, compared to analysts’ expectations of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.
39% and a negative net margin of 36.39%. As a group, research analysts predict that Arcturus Therapeutics Holdings Inc.
will post -2.22 EPS for the current year. About Arcturus Therapeutics ( Free Report ) Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases.
Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. See Also Want to see what other hedge funds are holding ARCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcturus Therapeutics Holdings Inc.
( NASDAQ:ARCT – Free Report ). Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
